

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

THIS PAGE BLANK (USPTO)



Kongeriget Danmark

Patent application No.: 0420./98
Date of filing: 25 Mar 1998
Applicant: Nebo Industries A/S, Frederiksborgvej 27,
4000 Roskilde, DK

This is to certify the correctness of the following information:

The attached photocopy is a true copy of the following document:

- The specification and claims as filed with the application on the filing date indicated above.



Erhvervsministeriet
Patentdirektoratet

TAASTRUP 23 Mar 1999

Heidi Meldgaard Nielsen

Heidi Meldgaard Nielsen
Assistent



THIS PAGE BLANK (USPTO)



0420/9825 MRS. 98

Sim/TSm/25249
25/03/98

Nebo Industries ApS, 4000 Roskilde

An iron-dextran compound for use as a component in a
therapeutical composition for prophylaxis or treatment of
iron-deficiency, a process for producing said iron-
dextran compound and use of said compound for the prep-
aration of a parenterally administrable therapeutical
composition.

Hoje Taastrup Boulevard 2
DK-2630 Taastrup
DenmarkPhone (+45) 43 99 55 11
Fax (+45) 43 99 99 11
<http://www.ipb.dk>
e-mail ipb@ipb.dkFédération Internationale des
Conseils en Propriété Industrielle

AN IRON-DEXTRAN COMPOUND FOR USE AS A COMPONENT IN A
THERAPEUTICAL COMPOSITION FOR PROPHYLAXIS OR TREATMENT
OF IRON-DEFICIENCY, A PROCESS FOR PRODUCING SAID IRON-
DEXTRAN COMPOUND AND USE OF SAID COMPOUND FOR THE PREP-
5 ARATION OF A PARENTERALLY ADMINISTABLE THERAPEUTICAL
COMPOSITION

BACKGROUND OF THE INVENTION AND PRIOR ART

10 Iron-deficiency anemia has been described as one
of the most common - possibly the most common - patho-
logical conditions among humans when viewed on a global
basis. Also in modern farm-breeding of pigs and other
domestic animals iron-deficiency anemia is a problem
15 unless suitable prophylactic measures are taken.

Although iron-deficiency anemia can often be pre-
vented or cured by oral administration of iron-contain-
ing preparations, it is in many cases preferred to use
parenterally administable iron preparations to avoid
20 variations in bioavailability of oral administrations
and to ensure effective administration.

Therefore, iron-containing preparations for
parenteral use, that means subcutaneous, intramuscular
or intravenous administration, have for many years been
25 at the disposal of the veterinary or human medical
practitioner.

Although various iron-containing substances have
been used or suggested as components in parenterally
injectable preparations against iron-deficiency anemia,
30 the most common preparations accepted today are such
which comprise a combined product of ferric oxy-
hydroxide (or ferric hydroxide) in association with
dextran. Dextran is a polymeric carbohydrate produced
by the microorganisms *Leuconostoc mesenteroides*.

An iron-containing preparation for parenteral injection should obviously satisfy several requirements including ready availability of the iron for haemoglobin synthesis, absence of local or general side-effects and stability on storage enabling a satisfactory shelf-life at ambient temperature.

Iron-dextran preparations for the treatment of anemia have been marketed for decades, and many variations in the manufacturing process and in the selection of starting materials have been suggested with a view to improving the stability of such preparations and to decrease the amount of side effects obtained at their administration.

As examples of patents dealing with these problems the following may be cited:

US 2,885,393 (1959) describes a basal process of producing an iron-dextran complex in which the average molecular weight of the dextran is 30,000 to 80,000 Daltons or lower. The suitability of these complexes for human therapy does not appear from this patent specification.

US Re. 24,642 (1959) comprises a detailed explanation of the requirements to an iron solution intended for intramuscular injection, incorporated herein by reference. The patent deals with a substantially nonionic complex of ferric hydroxide with a dextran having an average intrinsic viscosity at 25°C of about 0.025 to about 0.25, as well as a process for preparing such a complex by contacting a dextran as described with ferric hydroxide formed *in situ* by reaction between a ferric salt and an alkali base. No information as to the desired molecular weight of the dextran is given, and no chemical modification of the dextran, apart from a partial depolymerisation, is suggested.

US 3,093,545 (1963). This patent discloses some details such as temperatures and pH-values in an improved method of preparing a product apparently very similar to the one prepared in the last mentioned above patent.

GB 1,200,902 (1970) teaches that in contrast to preparing the ferric hydroxide *in situ* it is advantageous to preform the ferric hydroxide under controlled conditions since such ferric hydroxide will readily form complexes with dextrans. It is stated that not only partially depolymerised dextran having a weight average molecular weight in the range of for example 500-50,000 Daltons, preferably in the range 1,000-10,000 Daltons, but also modified forms or derivatives of dextran such as hydrogenated dextrans or oxidised dextrans or alkali treated dextrans come into consideration as theoretical possibilities. However, the only dextrans specifically mentioned are oxidized dextrans having an average molecular weight of 3,000 and 5,000 Daltons, resp.. The ferric hydroxide is preprepared before contact with the dextran. This means that the resulting product consists of ferric oxyhydroxide on which the dextran forms a coating in contrast to the more homogeneous products formed by precipitating the ferric hydroxide *in situ*, that means in the presence of the dextran.

DK 117,730 (1970) deals with a process in which hydrogenated dextran having a molecular weight between 2,000 and 10,000 Daltons is reacted with ferric hydroxide in aqueous medium. The average molecular weight of the dextran used in the embodiment examples is not indicated. However, the intrinsic viscosity is stated as approximately 0,05 which could correspond to an average molecular weight of approximately 5,000 Daltons.

DK 122,398 (1972) also discloses the use of hydrogenated dextran for preparing complex compounds with ferric hydroxide, and it is explained that a substantial lower toxicity is obtained than when non-hydrogenated dextran is used. The subject of the patent is a process in which moist ferric hydroxide is mixed with dry hydrogenated dextran, and after optional addition of citric acid or citrate the mixture is heated and purified.

10 US 3,697,502 (1972) discloses a process for producing an iron-dextran preparation in which citric acid is added to the dextran and a simultaneous addition of alkali metal hydroxide solution and ferric chloride solution is made. The average molecular weight of the dextran is between 3,000 and 20,000 Daltons. The dextran used in the embodiment examples has a molecular weight of 7,000 and 10,000 Daltons, resp..

DK 129,353 (1974) is directed on an analogy process for producing a ferric hydroxide-dextran derivative at an average molecular weight of the dextran of at the most 50,000 Daltons, and the terminal groups of the polymer chains thereof have been modified to convert the terminal reducing anhydroglucose unit into a corresponding carboxylic acid group. Although the limits indicated for molecular weight of the dextran are very broad, viz. from 500 to 50,000 Daltons, preferably from 1,000 to 10,000 Daltons, the only exemplified dextran has an average molecular weight of 5,000 Daltons.

30 DK 129,942 (1974) has similarity to the above last mentioned DK patent and deals with the manufacture of ferric hydroxide complexes with dextran hepton acid or dextrine hepton acid. The hepton acids are prepared by hydrolyzing the corresponding cyanhydrids.

US 4,827,945 (1989) and 5,102,652 (1992) both deal with superparamagnetic metal oxides such as iron oxides coated with or associated with polymeric materials such as dextran. The polymer is contacted with a mixture of the metal oxides in two different oxidation stages to produce a superparamagnetic combined product which is afterwards oxidized to transform all the metal oxide into the highest of said oxidation steps. The product is especially useful as contrast agent in magnetic resonance imaging in medical diagnosis. However, it is also mentioned that they can be used for treatment of iron-deficiency anemia. The molecular weight of the polymers, including carbohydrates such as dextran are preferably from 5,000 to 250,000 Daltons.

15 In spite of the several attempts to improve iron-dextran preparations for treatment of anemia, as reflected in the above patents, the preparations prepared according to the state of the art have still some drawbacks.

20 This is a result of the fact that in some patients the preparations may cause delayed hypersensitivity, or severe anaphylactic side effects, resulting f.inst. in dyspnea, hypotension, shock and death. Also other toxic reactions might be observed.

25 Besides, several of the prior art preparations are not able to meet current requirements as to stability. Lacking stability may manifest itself as gelatination of the liquid or precipitation of iron hydroxide or oxyhydroxide.

30

SUMMARY OF THE INVENTION

Based on investigations, tests and practical experiences we have now realized that the above mentioned drawbacks are associated with the presence of insuffi-

ciently hydrolyzed relatively high molecular weight dextran, although in tiny amounts, in the dextran used as starting material, as well as with the presence of low molecular weight saccharides therein.

5 It is generally recognized that high molecular weight dextrans involve a greater risk for anaphylactic reactions than do low molecular weight dextrans. Actually, it is current practice to reduce the risk for anaphylactic reactions when infusing clinical dextrans
10 by a pre-treatment of the patient by injection of low molecular weight dextran such as a dextran having a weight average molecular weight Mw of approximately 1,000 Daltons.

The manufacture of dextran usually involves acid
15 hydrolysis of dextrans of higher molecular weight followed by isolation and purifying operations including precipitation of the dextran, e.g. from an aqueous solution by addition of e.g. an alcohol.

By such a precipitation not only the desired frac-
20 tions of the dextran precipitate, but also any dextran of higher molecular weight will precipitate, for which reason the recovered dextran fraction often contains high molecular weight dextrans which have not been cleft in the preceding acid hydrolysis.

25 Since even very small concentrations of high molecular weight dextrans are able to cause unpredictable and often rather severe anaphylactic reactions, it is a feature of the present invention that the presence of such dextrans must be avoided by substituting or sup-
30 plementing the conventional precipitation processes by membrane processes capable of very efficiently eliminating the presence of high molecular weight dextrans before the desired dextran fraction is contacted with the iron compounds.

However, we have experienced that the removal of higher molecular weight dextrans from the desired dextran fraction having a weight average molecular weight of e.g. 1,000 Daltons, does not ensure that the resulting iron- dextran will be non-toxic and stable. It has also been revealed that the presence of low molecular weight carbohydrates such as monosaccharides resulting from the hydrolysis process creates difficulties.

10 The presence of such saccharides has hitherto been regarded as being of only minor importance. However, when the dextran containing such saccharides is reacted with iron, by precipitating ferric hydroxide in a solution thereof, not only dextran-iron association com-
15 pounds are formed, but also the saccharides combine with the iron to form complex or association compounds.

However, these saccharide based iron compounds are far less stable than the dextran-iron compounds, and in aqueous solution they give rise to a certain concentra-
20 tion of free ferric ions and of low molecular weight saccharides, such as glucose.

As it is well known, free ferric ions exert a toxic action when present in preparations for parenteral administration. Besides, it has turned out
25 that not only ferric ions but also low molecular weight saccharides cause instability of an aqueous iron-dextran solution, because of precipitation and/or gel-forming reactions possibly resulting in a complete solidification of the solution within days or months.
30 Besides, the presence of low molecular weight saccharides seems to increase the parenteral toxicity of an iron-dextran solution, apparently because the saccharides interfere with the binding of the iron compounds to the dextran, thereby forming free or only weakly
35 bound ferric ions.

Although the binding between the low molecular weight saccharides and the iron compounds, as it follows from the above, is rather weak, it is sufficient for impeding an efficient removal of the saccharides and the free iron compounds by the dialysis process to which it is customary to subject the iron-dextran solution as an after-treatment.

Therefore, it is a further important feature of the invention that the dextran fraction must be purified by membrane processes removing low molecular weight saccharides before it is used in the reaction where the iron-containing complex or association compounds are formed.

The present invention thus deals with iron-dextran compounds having an extremely low frequency of undesired side effects and being satisfactory stable, also during sterilization and storage as aqueous solutions, which iron-dextran compound can be used as component in a therapeutical composition for prophylaxis or treatment of iron-deficiency in animal or human subjects by parenteral administration, the iron-dextran compound being characterized in that it comprises hydrogenated dextran having a weight average molecular weight (Mw) between 700 and 1,400 Daltons, preferably approximately 1,000 Daltons, a number average molecular weight (Mn) of 400 to 1,400 Daltons and wherein 90% by weight of the dextran has molecular weights less than 2,700 Daltons and the Mw of the 10% by weight fraction of the dextran having the highest molecular weights is below 3,200 Daltons, in stable association with ferric oxyhydroxide.

It is believed that the reason why dextrans of the above defined molecular weight distribution have not found commercial applicability in the manufacture of iron-dextran compounds is that sufficient attention has

not been paid to the presence of low molecular weight saccharides for which reason toxicity and inferior stability have been experienced, and that sufficient attention has not been paid to the fact that the dex-
5 trans of weight average molecular weight around 1,000 Daltons are better tolerated by the human or animal organism than the higher molecular weight dextrans conventionally used in iron preparations.

When used for parenteral administration, the com-
10 pound in question is dissolved or dispersed in an aqueous liquid, and it may be marketed as such, preferably having an iron content of 5-20% w/v. On the other hand the compound is sufficiently stable to be dried without deterioration in a conventional drying process such as
15 spray-drying, for which reason the compound can also be marketed as sole or partial constituent of a dry powder. The iron content thereof will typically be 15-45% w/w.

In relatively low molecular weight dextrans as
20 those coming into consideration according to the present invention the influence of the terminal groups (partially hydrogenated aldehyde groups) on the polymer chains is substantially more pronounced than in dextrans of higher molecular weight, since, on a weight
25 basis, the number of functional terminal groups is higher. These functional terminal groups tend to increase instability by reactions involving Fe^{3+} and low molecular weight saccharides. Therefore, the absence of Fe^{3+} and low molecular weight saccharides is
30 even more important than when higher molecular weight dextrans are dealt with.

The invention also comprises a process for producing an iron-dextran compound as described above, which process is characterized in the following steps:

The molecular weight of dextran is reduced by hydrolysis, and the dextran is hydrogenated to convert functional aldehyde terminal groups into alcohol groups; the hydrogenated dextran as an aqueous solution 5 is combined with at least one water soluble ferric salt; base is added to the resulting solution to form ferric hydroxide, and the resulting mixture is heated to transform the ferric hydroxide into ferric oxy-hydroxide as an association compound with the dextran, 10 which process is characterized in, that after the hydrolysis but before being combined with the water soluble ferric salt, the dextran is purified by one or more membrane processes using a membrane having a cut-off value suitable for holding back dextran of molecular weight above 2,700 Daltons, possibly followed by 15 further hydrolysis, and followed by one or more membrane processes using membranes with a cut-off between 340 and 800 Daltons.

A preferred embodiment of the process comprises 20 the following:

preparing an aqueous solution comprising the purified hydrogenated dextran and at least one water-soluble ferric salt;

adjusting the pH of said aqueous solution to a 25 value above 10 by addition of a base;

heating the mixture to a temperature above 100°C until it turns to a black or dark brown colloidal solution which can be filtered through a 0.45 μm filter; and

30 further purification and stabilization using filtration, heating and membrane processes and addition of one or more stabilizers, and optionally drying the solution to obtain the desired iron-dextran compound as a stable powder. Injection liquids may be produced by 35 redissolving this powder, adjustment of pH, sterilizing

by filtration and filling into ampoules or vials. Sterilization may also be accomplished by autoclaving the filled ampoules or vials.

Alternatively the drying operation is omitted, and an injection liquid is produced from the purified solution without intermediate drying thereof.

In a further preferred embodiment the hydrogenation of the dextran is performed by means of sodium borohydride in aqueous solution.

10 The stabilization suitably takes place by addition of a salt of an organic hydroxy acid, preferably a citrate or a gluconate.

The invention also comprises use of a compound consisting of or containing a hydrogenated dextran 15 having a weight average molecular weight of 700-1,400 Daltons, preferably approximately 1,000 Daltons, a number average molecular weight (M_n) of 400 to 1,400 Daltons and wherein 90% by weight of the dextran has molecular weights less than 2,700 Daltons and the M_w of 20 the 10% by weight fraction of the dextran having the highest molecular weights is below 3,200 Daltons, in stable association with ferric oxyhydroxide for the preparation of a parenterally administrable therapeutic composition for prophylaxis or treatment of iron 25 deficiency anemia in animal or human subjects.

The invention is further illustrated by means of the following non-limiting examples.

EXAMPLE 1

30

(i) Hydrolysis and hydrogenation of dextran

2,522 kg hydrolyzed dextran collected as permeate from a membrane having a cut-off value $< 5,000$ Daltons, is hydrolyzed at pH 1.5 at a temperature of 95°C .

The hydrolysis is monitored chromatographically using gel permeation chromatography (GPC), and is terminated by cooling when the molecular weight of the material being hydrolyzed is estimated to have achieved the desired value, i.e. a weight average molecular weight of 700-1,400 Daltons.

By the hydrolysis low molecular weight dextran is produced but also glucose is formed. After cooling and neutralization the amount of glucose and very low molecular weight oligomers is reduced by membrane processes having a cut-off value of 340-800 Daltons. After this process, the content of dextran is determined by optical rotation ($\alpha_D^{20} \sim 200$) to be 1,976 kg, and the amount of reducing sugar is determined by use of Somogyi's reagent to be 36.8%.

The reducing capability is decreased by treatment with sodium borohydride. For the 1,976 kg dextran 57 kg sodium borohydride is added at basic pH.

After the sodium borohydride treatment, the reducing capability is determined to 1.5%.

Hereafter the solution is neutralized to pH < 7.0, and subsequently de-ionized. The average molecular weights and the molecular weight distribution is determined chromatographically.

25

The chromatography also reveals that the above conditions, viz. that 90% by weight of the dextran has molecular weights less than 2,700 Daltons and that the weight average molecular weight (Mw) of the 10% by weight fraction of the dextran having the highest molecular weights is below 3,200 Daltons, are fulfilled.

Mw is found to be 1,217 and Mn is 845 Daltons. The final amount of dextran after de-ionization is 1,320 kg - determined by optical rotation.

35

(ii) Synthesis of iron-dextran

120 kg dextran, produced as above, is as an 18% solution mixed with 150 kg $\text{FeCl}_3 \cdot 6\text{H}_2\text{O}$.

To the agitated mixture, 93 kg Na_2CO_3 as a saturated aqueous solution is added, and, thereafter, the pH is raised to 10.5 using 24 litres concentrated aqueous NaOH (27% w/v).

The mixture thus obtained is heated above 100°C until it turns to a black, dark brown colloidal solution which can be filtered through a $0.45 \mu\text{m}$ filter and subsequently cooled. After cooling the solution is neutralized using 12 litres concentrated hydrochloric acid to obtain a pH of 5.80 and is purified using membrane processes until the chloride content in the solution is less than 0.68% calculated on basis of a solution containing 5% w/v iron.

If the chloride content of the solution is less than desired to obtain an isotonic solution, sodium chloride is added and pH is finally adjusted to 5.6 and the solution is filtered through a $0.45 \mu\text{m}$ (or alternatively a $0.2 \mu\text{m}$) membrane filter.

The solution is spray dried and the iron-dextran powder is ready for marketing or for further processing.

As alternative to spray drying, the solution can be used for direct production of injection liquids having an iron content of e.g. 5%, as described above.

When using the iron-dextran powder for producing injection or infusion liquids the powder is re-dissolved in an aqueous medium, the pH is checked, and, if necessary, adjusted, and the solution is filled into ampoules or vials after being sterilized by filtration. Alternatively, the sterilization can take place by autoclaving after filling into ampoules or vials.

EXAMPLE 2

(i) Hydrolysis and hydrogenation of dextran

This portion of the synthesis is performed as described under (i) in Example 1 above, apart from the fact that 54 kg sodium borohydride is used and the reducing capability is thereby decreased to 3.0%.

(ii) Synthesis of iron-dextran

120 kg of the above mentioned dextran as an 18% solution is mixed with 300 kg $\text{FeCl}_3 \cdot 6\text{H}_2\text{O}$.

To the agitated mixture is added 180 kg Na_2CO_3 as a saturated aqueous solution, and thereafter the pH of the mixture is raised to pH 11.5 using 38 litres concentrated aqueous NaOH (27% w/v).

15 The mixture thus obtained is heated above 100°C until it turns to a black, dark brown colloidal solution and can be filtered through a $0.45 \mu\text{m}$ filter after which it is cooled. The cooled solution is neutralized, using 25 litres concentrated hydrochloric acid, to pH 5.60 and is purified using membrane processes until the chloride content is less than 1.1% calculated on basis of a solution containing 10% w/v iron.

25 Thereafter a hydroxy acid in the form of 6 kg citric acid is added, and pH is adjusted to a pH above 8.0 using NaOH, and the solution is stabilized by raising the temperature to above 100°C for 60 minutes.

Subsequently, pH is adjusted by means of concentrated hydrochloric acid to pH 5.6. In case the chloride content of the solution is less than desired, it is adjusted by adding NaCl.

Thereafter, the solution is filtered through a $0.45 \mu\text{m}$ (or $0.2 \mu\text{m}$) membrane filter.

The solution is spray dried and the iron-dextran powder is thus finished.

This powder is suitable for producing a liquid iron-dextran preparation containing approximately 10% w/v iron.

5 EXAMPLE 3

(i) Hydrolysis and hydrogenation of dextran

This portion of the synthesis is performed as in Example 2 above.

10

(ii) Synthesis of iron-dextran

80 kg of the above dextran as an aqueous 10% solution is mixed with 400 kg $\text{FeCl}_3 \cdot 6\text{H}_2\text{O}$.

To the agitated mixture 232 kg Na_2CO_3 is added as a saturated aqueous solution and thereafter the pH of the mixture is raised to 11.5 using 60 litres concentrated aqueous NaOH (27% w/v).

The above mentioned mixture is heated above 100°C until it turns to a black, dark brown colloidal solution and can be filtered through a $0.45\ \mu\text{m}$ filter after which it is cooled. The cold solution is neutralized using 15 litres concentrated hydrochloric acid to pH 5.60 and is purified using membrane processes until the chloride content is less than 1.8% calculated on basis of a solution containing 20% w/v iron.

Thereafter hydroxy acid, constituted of 8 kg citric acid, is added and pH is adjusted with NaOH to a value above 8.0, after which the solution is stabilized by raising the temperature to above 100°C for 60 minutes.

Thereafter pH is adjusted with concentrated hydrochloric acid to 5.6. In case the chloride content of the solution is less than desired, the chloride content is adjusted by adding NaCl. The solution is filtered through a $0.45\ \mu\text{m}$ (or $0.2\ \mu\text{m}$) membrane filter.

The solution is spray dried and the iron-dextran powder is finished. This powder is suitable for producing a liquid preparation containing 20% w/v iron.

- 5 In all three examples, the yield of iron-dextran powder is above 95%, calculated on basis of the iron used in the process.

P A T E N T C L A I M S

1. An iron-dextran compound for use as component in a therapeutical composition for prophylaxis or treatment of iron-deficiency in animal or human subjects by parenteral administration, comprising hydrogenated dextran having a weight average molecular weight (Mw) between 700 and 1,400 Daltons, preferably approximately 1,000 Daltons, a number average molecular weight (Mn) of 400 to 1,400 Daltons and wherein 90% by weight of the dextran has molecular weights less than 2,700 Daltons and the Mw of the 10% by weight fraction of the dextran having the highest molecular weights is below 3,200 Daltons, in stable association with ferric oxyhydroxide.
2. A compound according to claim 1, characterized in being sole or partial constituent of a dry powder.
3. A compound according to claim 2, characterized in that the powder of which the compound is a sole or partial constituent has an iron content of 15-45% w/w.
4. A compound according to claim 1, characterized in being dissolved or dispersed in an aqueous liquid.
5. A compound according to claim 4, characterized in that it is dissolved or dispersed in the aqueous liquid in such an amount that the iron content in the resulting solution or dispersion is 5-20% w/v.
6. A process for producing an iron-dextran compound as defined in claim 1, in which the molecular weight of dextran is reduced by hydrolysis and the dextran is hydrogenated to convert functional aldehyde terminal groups into alcohol groups; the hydrogenated dextran as an aqueous solution is combined with at

least one water soluble ferric salt; base is added to the resulting solution to form ferric hydroxide, and the resulting mixture is heated to transform the ferric hydroxide into ferric oxyhydroxide as an association
5 compound with the dextran, c h a r a c t e r i z e d in that after the hydrolysis but before being combined with the water soluble ferric salt, the dextran is purified by one or more membrane processes having a cut-off value suitable for holding back dextran of
10 molecular weight above 2,700 Daltons, possibly followed by further hydrolysis and followed by one or more membrane processes having a cut-off between 340 and 800 Daltons.

7. A process according to claim 6, c h a r a c -
15 t e r i z e d in the following steps

preparing an aqueous solution comprising the resulting hydrogenated dextran and at least one water soluble ferric salt;

adjusting the pH of said aqueous solution to a value
20 above 10 by addition of a base;

heating the mixture to a temperature above 100°C until it turns to a black, dark brown colloidal solution and is filterable through a 0.45 μ m filter; and

purification and stabilisation of the solution
25 using filtration, heating and membrane processes and addition of one or more stabilizers, and, optionally, drying the solution to obtain the desired iron-dextran compound as a stable powder.

8. A process according to claim 6, c h a r a c -
30 t e r i z e d in that the hydrogenation of the dextrans is performed by means of sodium borohydride in aqueous solution.

9. A process according to claim 7, c h a r a c -
t e r i z e d in that the stabilisation addition of at

least one salt of an organic hydroxy acid, preferably selected from citrates and gluconates.

10. Use of a compound comprising a hydrogenated - dextran having a weight average molecular weight (Mw) 5 between 700 and 1,400 Daltons, preferably approximately 1,000 Daltons, a number average molecular weight (Mn) of 400 to 1,400 Daltons and wherein 90% by weight of the dextran has molecular weights less than 2,700 Daltons and the Mw of the 10% by weight fraction of the 10 dextran having the highest molecular weights is below 3,200 Daltons, in stable association with ferric oxyhydroxide for the preparation of a parenterally administrable therapeutical composition for prophylaxis or treatment of iron-deficiency anemia in animal or human 15 subjects.

11. A process for producing an injection liquid containing a compound according to claim 1, c h a - r a c t e r i z e d in dissolving the compound as a dry powder in an aqueous medium, adjusting the pH, if 20 necessary, optionally adding stabilizer, and sterilizing the liquid by filtration before filling into ampoules or vials or by autoclave treatment after filling into such ampoules or vials.

12. A process for producing an injection liquid 25 containing a compound according to claim 1, c h a - r a c t e r i z e d in that a liquid resulting from the process of claim 6 is purified, adjusted as to iron content and pH value, stabilized and sterilized by filtration before being filled into ampoules or vials 30 or by autoclave treatment after being filled into ampoules or vials.

Wm. S.